drugset / Trial / NCT03132155

QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

NCT03132155

Phase 2 Terminated 8 enrolled NantPharma, LLC
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 2 study that will assess the efficacy of AMG 337 in subjects with advanced or metastatic clear cell sarcoma that contains the EWSR1-ATF1 gene fusion.

Timeline

Start
2018-08-29
Primary completion
2021-08-13
Completion
2021-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject AMG 337 Small molecule

Indications